Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Edhyana Sahiratmadja, Ika Agus Rini, Simeon Penggoam, Afandi Charles, Ani Melani Maskoen & Ida Parwati. (2021) Acetylator Status Among Newly Diagnosed and Recurrent Tuberculosis Patients from Kupang, Eastern Part of Indonesia. Pharmacogenomics and Personalized Medicine 14, pages 737-744.
Read now
Read now
Ilaria Motta, Andrea Calcagno & Stefano Bonora. (2018) Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?. Expert Opinion on Drug Metabolism & Toxicology 14:1, pages 59-82.
Read now
Read now
Bella Devaleenal Daniel, Geetha Ramachandran & Soumya Swaminathan. (2017) The challenges of pharmacokinetic variability of first-line anti-TB drugs. Expert Review of Clinical Pharmacology 10:1, pages 47-58.
Read now
Read now
Articles from other publishers (9)
Melisa Intan Barliana, Nadiya Nurul Afifah, Vycke Yunivita & Rovina Ruslami. (2023) Genetic polymorphism related to ethambutol outcomes and susceptibility to toxicity. Frontiers in Genetics 14.
Crossref
Crossref
N. M. Krasnova, S. G. Efremenko, N. E. Evdokimova, O. I. Filippova, Y. V. Chertovskikh, E. A. Alekseeva, O. V. Tatarinova, A. I. Gotovtseva, E. S. Prokopev, A. F. Kravchenko, A. I. Vengerovskiy & D. A. Sychev. (2022) Influence of the NAT2 gene polymorphic markers on the effectiveness and safety of treatment in patients with newly diagnosed pulmonary tuberculosis based on peripheral red blood cell dynamics. Antibiotics and Chemotherapy 66:9-10, pages 30-38.
Crossref
Crossref
Vandana Saini, Anju Goyal & Ajay Kumar. (2022) Isoniazid: An Exploratory Review. Asian Journal of Organic & Medicinal Chemistry 7:1, pages 1-10.
Crossref
Crossref
Monique Opperman, Du Toit Loots, Mari van Reenen, Katharina Ronacher, Gerhard Walzl & Ilse du Preez. (2021) Chronological Metabolic Response to Intensive Phase TB Therapy in Patients with Cured and Failed Treatment Outcomes. ACS Infectious Diseases 7:6, pages 1859-1869.
Crossref
Crossref
Abul K. Azad, Christopher Lloyd, Wolfgang Sadee & Larry S. Schlesinger. (2020) Challenges of Immune Response Diversity in the Human Population Concerning New Tuberculosis Diagnostics, Therapies, and Vaccines. Frontiers in Cellular and Infection Microbiology 10.
Crossref
Crossref
Petro B. Antonenko, Kateryna O. O. Antonenko, Valentin I. Kresyun, Olga Żuk & Kateryna G. Lobashova. (2019) Serum isoniazid concentration in the patients as an indicator of the effectiveness and toxicity of tuberculosis treatment. Polish Annals of Medicine.
Crossref
Crossref
Chaitanya K. Jaladanki, Akbar Shaikh & Prasad V. Bharatam. (2017) Biotransformation of Isoniazid by Cytochromes P450: Analyzing the Molecular Mechanism using Density Functional Theory. Chemical Research in Toxicology 30:11, pages 2060-2073.
Crossref
Crossref
James E Gomez, Benjamin B Kaufmann-Malaga, Carl N Wivagg, Peter B Kim, Melanie R Silvis, Nikolai Renedo, Thomas R Ioerger, Rushdy Ahmad, Jonathan Livny, Skye Fishbein, James C Sacchettini, Steven A Carr & Deborah T Hung. (2017) Ribosomal mutations promote the evolution of antibiotic resistance in a multidrug environment. eLife 6.
Crossref
Crossref
Henrik Cordes, Christoph Thiel, Hélène E. Aschmann, Vanessa Baier, Lars M. Blank & Lars Kuepfer. (2016) A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy. Antimicrobial Agents and Chemotherapy 60:10, pages 6134-6145.
Crossref
Crossref